Home
  >  
Section 66
  >  
Chapter 65,217

In Vitro and in Vivo Activities of Contezolid (MRX-I) against Mycobacterium tuberculosis

Shoen, C.; DeStefano, M.; Hafkin, B.; Cynamon, M.

Antimicrobial Agents and ChemoTherapy 62(8)

2018

ISSN/ISBN: 1098-6596
PMID: 29784848
DOI: 10.1128/aac.00493-18
Accession: 065216151
Download citation:  
Text
  |  
BibTeX
  |  
RIS
The in vitro activity of contezolid (MRX-I) against clinical isolates of Mycobacterium tuberculosis was evaluated using a microtiter broth dilution assay. MRX-I was as effective as linezolid (LZD) in vitro MRX-I and LZD were subsequently studied in BALB/c mice infected intranasally with M. tuberculosis Erdman. MRX-I and LZD at 100 mg/kg significantly reduced the bacterial load in lungs compared to the untreated early and late controls.

Full Text Article emailed within 0-6 h: $19.90




Related References

An, H.; Sun, W.; Liu, X.; Wang, T.; Qiao, J.; Liang, J. 2023: In vitro activities of contezolid (MRX-I) against drug-sensitive and drug-resistant Mycobacterium tuberculosis Microbiology Spectrum 2023: E0462722
Alvirez-Freites, E.J.; Carter, J.L.; Cynamon, M.H. 2002: In vitro and in vivo activities of gatifloxacin against Mycobacterium tuberculosis Antimicrobial Agents and ChemoTherapy 46(4): 1022-1025
Xu, J.; Wang, B.; Fu, L.; Zhu, H.; Guo, S.; Huang, H.; Yin, D.; Zhang, Y.; Lu, Y. 2019: In Vitro and in Vivo Activities of the Riminophenazine TBI-166 against Mycobacterium tuberculosis Antimicrobial Agents and ChemoTherapy 63(5)
Ji, B.; Lounis, N.; Truffot-Pernot, C.; Grosset, J. 1995: In vitro and in vivo activities of levofloxacin against Mycobacterium tuberculosis Antimicrobial Agents and ChemoTherapy 39(6): 1341-1344
Lu, Y.; Zheng, M.-Q.; Wang, B.; Zhao, W.-J.; Li, P.; Chu, N.-H.; Liang, B.-W. 2008: Activities of clofazimine against Mycobacterium tuberculosis in vitro and in vivo Zhonghua Jie he He Hu Xi Za Zhi 31(10): 752-755
Upton, A.M.; Cho, S.; Yang, T.J.; Kim, Y.; Wang, Y.; Lu, Y.; Wang, B.; Xu, J.; Mdluli, K.; Ma, Z.; Franzblau, S.G. 2015: In vitro and in vivo activities of the nitroimidazole TBA-354 against Mycobacterium tuberculosis Antimicrobial Agents and ChemoTherapy 59(1): 136-144
Gay, J.D.; Deyoung, D.R.; Roberts, G.D. 1984: In vitro activities of norfloxacin and ciprofloxacin against mycobacterium tuberculosis mycobacterium avium complex mycobacterium chelonei mycobacterium fortuitum and mycobacterium kansasii Antimicrobial Agents and Chemotherapy 26(1): 94-96
Hirata, T.; Saito, H.; Tomioka, H.; Sato, K.; Jidoi, J.; Hosoe, K.; Hidaka, T. 1995: In vitro and in vivo activities of the benzoxazinorifamycin KRM-1648 against Mycobacterium tuberculosis Antimicrobial Agents and ChemoTherapy 39(10): 2295-2303
Ji, B.; Lounis, N.; Maslo, C.; Truffot-Pernot, C.; Bonnafous, P.; Grosset, J. 1998: In vitro and in vivo activities of moxifloxacin and clinafloxacin against Mycobacterium tuberculosis Antimicrobial Agents and ChemoTherapy 42(8): 2066-2069
Ji, B.; Truffot-Pernot, C.; Grosset, J. 1991: In vitro and in vivo activities of sparfloxacin (AT-4140) against Mycobacterium tuberculosis Tubercle 72(3): 181-186
Ashtekar, D.R.; Costa-Perira, R.; Nagrajan, K.; Vishvanathan, N.; Bhatt, A.D.; Rittel, W. 1993: In vitro and in vivo activities of the nitroimidazole CGI 17341 against Mycobacterium tuberculosis Antimicrobial Agents and Chemotherapy 37(2): 183-186
Jagannath, C.; Allaudeen, H.S.; Hunter, R.L. 1995: Activities of poloxamer CRL8131 against Mycobacterium tuberculosis in vitro and in vivo Antimicrobial Agents and ChemoTherapy 39(6): 1349-1354
Saito, H.; Tomioka, H.; Sato, K.; Hirata, T.; Hidaka, T. 1994: In vitro and in vivo activities of benzoxazinorifamycin KRM-1648 against Mycobacterium tuberculosis Abstracts of the General Meeting of the American Society for Microbiology 94: 192
Falzari, K.; Zhu, Z.; Pan, D.; Liu, H.; Hongmanee, P.; Franzblau, S.G. 2005: In vitro and in vivo activities of macrolide derivatives against Mycobacterium tuberculosis Antimicrobial Agents and ChemoTherapy 49(4): 1447-1454
Zhang, M.; Sala, C.; Dhar, N.; Vocat, A.; Sambandamurthy, V.K.; Sharma, S.; Marriner, G.; Balasubramanian, V.; Cole, S.T. 2014: In vitro and in vivo activities of three oxazolidinones against nonreplicating Mycobacterium tuberculosis Antimicrobial Agents and ChemoTherapy 58(6): 3217-3223
Hearn, M.J.; Cynamon, M.H. 2003: In vitro and in vivo activities of acylated derivatives of isoniazid against mycobacterium tuberculosis Drug Design and Discovery 18(4): 103-108
Xu, G.; Li, H.; Liu, S. 1995: Comparison of in-vitro and in-vivo activities of enoxacin and ofloxacin against the Mycobacterium tuberculosis Zhonghua Jie he He Hu Xi Za Zhi 18(3): 175-177; 192
Lu, J.; Yue, J.; Wu, J.; Luo, R.; Hu, Z.; Li, J.; Bai, Y.; Tang, Z.; Xian, Q.; Zhang, X.; Wang, H. 2010: In vitro and in vivo activities of a new lead compound I2906 against Mycobacterium tuberculosis Pharmacology 85(6): 365-371
Guo, S.; Fu, L.; Wang, B.; Chen, X.; Zhao, J.; Liu, M.; Lu, Y. 2020: In vitro and in vivo antimicrobial activities of a novel piperazine-containing benzothiazinones candidate TZY-5-84 against Mycobacterium tuberculosis Biomedicine and PharmacoTherapy 131: 110777
Yamamoto, T.; Amitani, R.; Suzuki, K.; Tanaka, E.; Murayama, T.; Kuze, F. 1996: In vitro bactericidal and in vivo therapeutic activities of a new rifamycin derivative, KRM-1648, against Mycobacterium tuberculosis Antimicrobial Agents and ChemoTherapy 40(2): 426-428